6 unchanged sentences
Name Age Position
−Removed: Gonzalez 70 Chairman of the Board and Chief Executive Officer
−Removed: Michael 53 President and Chief Operating Officer
+Added: Gonzalez 71 Executive Chairman of the Board and Retired Chief Executive Officer
+Added: Michael 54 Chief Executive Officer
Reents 57 Executive Vice President, Chief Financial Officer
6 unchanged sentences
Stewart 56 Executive Vice President, Chief Commercial Officer
−Removed: 58 Senior Vice President, Controller
−Removed: 62 Senior Vice President, Chief Scientific Officer, Global Research
Roopal Thakkar, M.D.
−Removed: 52 Senior Vice President, Chief Medical Officer, Global Therapeutics
+Added: 53 Executive Vice President, Research & Development and Chief Scientific Officer
+Added: Buckbee 59 Senior Vice President, Controller
_______________________________________________________________________________
−Removed: Gonzalez is the Chairman and Chief Executive Officer of AbbVie, a position he has held since 2013.
+Added: Gonzalez is the Executive Chairman of the Board.
+Added: Gonzalez served as Chairman and Chief Executive Officer of AbbVie from 2013 to June 2024.
He served as Abbott’s Executive Vice President of the pharmaceutical products group from July 2010 to December 2012, and was responsible for Abbott’s worldwide pharmaceutical business, including commercial operations, research and development, and manufacturing.
2 unchanged sentences
Abbott’s President and Chief Operating Officer; President, Chief Operating Officer of Abbott’s Medical Products Group; Senior Vice President and President of Abbott’s former Hospital Products Division; Vice President and President of Abbott’s Health Systems Division; and Divisional Vice President and General Manager for Abbott’s Diagnostics Operations in the United States and Canada.
−Removed: On February 14, 2024, the Board of Directors of AbbVie unanimously selected Mr.
+Added: On February 13, 2025, the Board of Directors of AbbVie unanimously elected Mr.
Michael to succeed Mr.
−Removed: Gonzalez as the Company's Chief Executive Officer.
−Removed: Gonzalez will retire from the role of Chief Executive Officer and become Executive Chairman of the Board of Directors, effective July 1, 2024.
−Removed: Michael is AbbVie’s President and Chief Operating Officer.
−Removed: Michael previously served as Vice Chairman and President from June 2022 to July 2023, as Vice Chairman, Finance and Commercial Operations and Chief Financial Officer from June 2021 to June 2022, as Executive Vice President, Chief Financial Officer from 2019 to 2021, as Senior Vice President, Chief Financial Officer from 2018 to 2019 and as Vice President, Controller from 2017 to 2018.
+Added: Gonzalez as Chairman of the Board of Directors, effective July 1, 2025, at which time Mr.
+Added: Gonzalez will retire from the Board.
+Added: Michael is AbbVie’s Chief Executive Officer, a position he has held since July 2024, and serves on its Board of Directors.
+Added: Michael previously served as President and Chief Operating Officer from July 2023 to June 2024, as Vice Chairman and President from June 2022 to July 2023, as Vice Chairman, Finance and Commercial Operations and Chief Financial Officer from June 2021 to June 2022, as Executive Vice President, Chief Financial Officer from 2019 to 2021, as Senior Vice President, Chief Financial Officer from 2018 to 2019 and as Vice President, Controller from 2017 to 2018.
He served as AbbVie's Vice President, Treasurer from 2015 to 2016, as Vice President, Controller, Commercial Operations from 2013 to 2015 and as Vice President, Financial Planning and Analysis from 2012 to 2013.
2 unchanged sentences
Michael joined Abbott in 1993 and was first appointed as an AbbVie corporate officer in March 2017.
−Removed: On February 14, 2024, the Board of Directors of AbbVie unanimously selected Mr.
+Added: On February 13, 2025, the Board of Directors of AbbVie unanimously elected Mr.
Michael to succeed Mr.
−Removed: Gonzalez as the Company's Chief Executive Officer.
−Removed: Gonzalez will retire from the role of Chief Executive Officer and become Executive Chairman of the Board of Directors, effective July 1, 2024.
−Removed: The Board also appointed Mr.
−Removed: Michael as a member of the Board of Directors as a Class II director, effective July 1, 2024.
+Added: Gonzalez as Chairman of the Board of Directors, effective July 1, 2025, at which time Mr.
+Added: Gonzalez will retire from the Board.
Reents is AbbVie’s Executive Vice President, Chief Financial Officer.
24 unchanged sentences
Stewart joined Abbott in 1992 and was first appointed as an AbbVie corporate officer in December 2018.
+Added: Thakkar serves as AbbVie's Executive Vice President, Research & Development and Chief Scientific Officer.
+Added: He previously served as Senior Vice President of Development and Regulatory Affairs and Chief Medical Officer at AbbVie from 2022 until 2023, as Vice President, Global Regulatory Affairs and R&D Quality Assurance from 2019 to 2022, and as Vice President, Global Regulatory Affairs from 2015 to 2019.
+Added: Thakkar joined Abbott in 2003 and was first appointed as a corporate officer in December 2023.
Buckbee is AbbVie’s Senior Vice President, Controller.
−Removed: Buckbee previously served as AbbVie’s Vice President, Controller, Global Commercial Operations from January 2016 until March 2023, and as Vice President, Controller, US Commercial Operations from AbbVie’s separation from Abbott in 2013 until December 2015.
+Added: Buckbee previously served as AbbVie’s Vice President, Controller, Global Commercial Operations from January 2016 until March 2023, and as Vice President, Controller, U.S.
+Added: Commercial Operations from AbbVie’s separation from Abbott in 2013 until December 2015.
Buckbee joined Abbott in 1991 and held several positions in the finance organization.
−Removed: Hudson is AbbVie's Senior Vice President, Chief Scientific Officer, Global Research.
−Removed: He previously served as Senior Vice President, Research & Development and Chief Scientific Officer from 2019 to 2023, and as Vice President, Head of Oncology Discovery and Early Development from 2016 to 2019.
−Removed: Prior to joining AbbVie, Dr.
−Removed: Hudson served at the Ontario Institute for Cancer Research as President and Scientific Director.
−Removed: He also previously served as Founder and Director of the McGill University and Genome Quebec Innovation Centre and Assistant Director of the Whitehead/MIT Center for Genome Research.
−Removed: Hudson was first appointed as an AbbVie corporate officer in July 2019.
−Removed: Thakkar serves as AbbVie's Senior Vice President, Chief Medical Officer, Global Therapeutics.
−Removed: He previously served as Senior Vice President of Development and Regulatory Affairs and Chief Medical Officer at AbbVie from late 2022 until early December 2023, as Vice President, Global Regulatory Affairs and R&D Quality Assurance from 2019 to 2022, and as Vice President, Global Regulatory Affairs from 2015 to 2019.
−Removed: Thakkar joined Abbott in 2003 and was first appointed as a corporate officer in December 2023.
The executive officers of AbbVie are elected annually by the board of directors.
5 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.